Table 1.
Summary of drug treatment comparing rat and human doses
| Animal model | Pioglitazone |
|||
|---|---|---|---|---|
| Drug treatment duration | Dose in rats mg/kg BW | Equivalent human dose mg/day | % decrease in KW/BW * | |
| PCK rat - females | 14 weeks (weeks 4-18) | 20 | 227 | 20.7 |
| PCK rat - males | 7 weeks (weeks 3-10) | 20 | 227 | 15.8 |
| PCK rat - females | 7 weeks (week 3-10) | 4 | 45 | 28.7 |
| PCK rat - males | 7 weeks (week 3-10) | 4 | 45 | 26.3 |
| Wpk-/- rats | Day 5-18 | 2.0 | 22.7 | -7.6 |
| Wpk-/- rats | Day 5-18 | 0.2 | 2.27 | 16.6 |
| Rosiglitazone |
||||
| PCK rat (females) | 24 weeks (week 4-28) | 0.4 | 4.5 | -4.1 |
| PCK rat (females) | 24 weeks (week 4-28) | 0.04 | 0.45 | 10.6 |
Notes: The equivalent human dose was calculated using the metric established by the FDA [18] and normalized to a 70 kg human. For comparison, standard dosing in humans for the treatment of diabetes is 15, 30, and 45 mg/day for pioglitazone and 4 or 8 mg/day for rosiglitazone. Where no gender is specified, both male and female animals were combined. Positive values denote a lower kidney mass as a percentage of body weight of treated animals when compared to untreated animals. The calculated values for the PCK rats treated with pioglitazone were taken from Blazer-Yost et al. [5] and the values for Wpk:-/- rats treated with pioglitazone and for PCK rats treated with rosiglitazone were calculated from the data obtained in the current study.